{"id":"NCT04241315","sponsor":"On Target Laboratories, LLC","briefTitle":"ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting","officialTitle":"A Phase 3, Randomized,Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-03-26","primaryCompletion":"2021-10-07","completion":"2021-11-01","firstPosted":"2020-01-27","resultsPosted":"2023-03-23","lastUpdate":"2023-03-23"},"enrollment":112,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Lung Neoplasms","Lung Cancer"],"interventions":[{"type":"DRUG","name":"OTL38 for Injection","otherNames":["CYTALUXâ„¢ (pafolacianine) injection"]},{"type":"DEVICE","name":"Near infrared camera imaging system","otherNames":[]}],"arms":[{"label":"Near-Infrared Imaging group","type":"EXPERIMENTAL"},{"label":"No Imaging Group","type":"OTHER"}],"summary":"This is a phase 3, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/PET/MRI or other imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to assess the safety and tolerability of single intravenous doses of OTL38.","primaryOutcome":{"measure":"Clinically Significant Events (CSE)","timeFrame":"1 day","effectByArm":[{"arm":"Full Analysis Set (FAS)","deltaMin":0.53,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":100},"commonTop":["Procedural pain","Pneumothorax","Nausea","Cough","Dyspnoea"]}}